亚毒性思普拉丁度诱导广泛的染色体,核和核细胞异常,与高恶性瘤相关,在获得耐药性发展之前:临床谨慎性的影响
John G Delinassios1, Robert M Hoffman2,3, George Koumakis1
1International Institute of Anticancer Research, Kapandriti, Attica, Greece.
PloS one
|December 26, 2024
概括
亚毒性思普拉丁水平在HeLa细胞中诱导显著的核,核细胞和染色体异常,表明遗传不稳定. 这些发现表明低剂量的思丁可能会促进恶性瘤,在临床应用中需要谨慎.
科学领域:
- 细胞生物学 细胞生物学
- 遗传学 遗传学 是一个
- 癌症研究 癌症研究
背景情况:
- 西斯是一种广泛使用的化疗剂.
- 目前对西斯的作用的理解主要是基于高度.
- 亚毒性思普拉丁度对细胞和染色体完整性的影响不太清楚.
研究的目的:
- 为了研究亚毒性思普拉丁水平对HeLa细胞中核,核细胞和染色体异常的影响.
- 为了评估由低剂量西斯普拉丁暴露诱导染色体不稳定.
- 了解在西斯普拉丁耐药性发展之前对恶性瘤的潜在影响.
主要方法:
- 希拉细胞被暴露在逐渐增加的西斯的亚毒性剂量 (0.01至0.2微克/毫升).
- 细胞使用Giemsa和银色染色技术进行染色.
- 进行染色体分析以检测异常和不稳定.
主要成果:
- 亚毒性思普拉丁诱导了显著的核异常 (例如,斑块,微核,碎片) 和核细胞变化 (不规则的形状,增加的数量).
- 观察到显著的染色体不稳定性,包括无倍体性,多倍体性,二心体和染色体交换.
- 这些异常在预先敏感化的细胞中加剧,突出显示了剂量依赖和累积效应.
结论:
- 亚毒性思普拉丁度的增加导致HeLa细胞中广泛的异常和染色体不稳定.
- 这种不稳定性与西斯普拉丁耐药性之前的恶性瘤潜力增加有关.
- 临床使用低剂量西斯丁应谨慎使用,因为可能促进恶性瘤的发生.
相关概念视频
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Abnormal Proliferation
4.3K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.3K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Adaptive Mechanisms in Cancer Cells
5.5K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.5K
Induced Pluripotent Stem Cells
3.8K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
3.8K
Mutagenicity and Carcinogenicity
1.1K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.1K


